Medical Device Reporting (MDR) is a U.S. Food and Drug Administration (FDA) requirement that mandates manufacturers, importers, and user facilities to report adverse events involving medical devices that may have caused or contributed to serious injury or death.
Under the Federal Food, Drug, and Cosmetic Act, MDR ensures the FDA collects safety data on devices after they enter the market. This includes incidents such as device malfunctions, design flaws, or misuse leading to harm. Reports must be submitted within specific timeframes depending on the severity and type of event.
The FDA uses MDR data to detect emerging safety issues, issue recalls, update labeling, and enforce regulatory actions. Failure to submit timely reports can result in enforcement actions, including warning letters or product seizures.
When a medical device causes or contributes to a serious injury or death, the responsible party must file an MDR report. The process begins with identifying whether the event meets the criteria for a reportable incident under FDA regulations.
For manufacturers and importers, the timeline is strict: a report must be filed within 15 calendar days of becoming aware of the incident. User facilities-such as hospitals or clinics-must report within 10 business days after learning of the event. These deadlines apply regardless of whether the event occurred in the U.S. or abroad.
Reports are submitted electronically via the FDA's Manufacturer and User Facility Device Experience (MAUDE) database. The system allows public access to anonymized data, enabling researchers, clinicians, and regulators to track device performance over time.
An MDR report must include specific information to be accepted by the FDA. Required fields include:
For example, a hospital using a ventilator reported a patient's respiratory failure due to a software glitch that failed to adjust oxygen levels. The report included the patient's age (68), the ventilator model (Philips Intellivue MP70), the serial number, and a detailed timeline of the event. The hospital submitted the report within 8 business days, meeting the deadline.
Manufacturers must also conduct root cause analysis and corrective actions. The FDA reviews these responses during inspections and audits. If a pattern emerges-such as multiple reports of a pacemaker failing in patients with certain heart conditions-the agency may initiate a recall or require updated warnings.
Many assume MDR applies only to high-risk devices like implantable defibrillators or surgical robots. However, the FDA requires reporting for all classes of devices, including Class I (low risk), such as bandages or stethoscopes, if they contribute to serious harm.
Another misconception is that only manufacturers are responsible. In reality, user facilities-including outpatient clinics, nursing homes, and ambulatory surgery centers-are legally obligated to report. A 2021 FDA audit found that nearly 30% of user facility reports were delayed beyond the 10-day window, often due to unclear internal policies.
Some believe that minor malfunctions don't need reporting. But even a small error-like a blood pressure monitor displaying incorrect readings-can lead to misdiagnosis and harm. The FDA defines "serious injury" broadly: it includes any injury requiring hospitalization, prolonged treatment, or permanent impairment.
MDR events fall into three categories based on severity and outcome:
| Event Type | Definition | Report Deadline | Example |
|---|---|---|---|
| Death | Device-related death confirmed by autopsy or clinical records | 15 days (manufacturer), 10 business days (facility) | A patient died after a faulty insulin pump delivered double the prescribed dose |
| Serious Injury | Injury requiring hospitalization, prolonged therapy, or permanent damage | Same as above | A surgical drill overheated during a hip replacement, causing tissue burns |
| Malfunction | Device failure that could lead to serious harm if not corrected | 15 days (manufacturer) | A cardiac catheter broke during insertion, requiring emergency retrieval |
These distinctions affect how the FDA prioritizes investigations. Death reports trigger immediate review. Malfunction reports may lead to field corrections or redesigns.
In 2019, the FDA received over 1,200 MDR reports related to Stryker's Rejuvenate and ABG II modular neck hip implants. Multiple reports described early wear, metal ion release, and revision surgeries due to loosening.
After analyzing MDR data, the FDA issued a Class I recall-its most urgent category-due to the risk of severe pain, nerve damage, and joint failure. The agency cited a 15% revision rate among patients within five years, far exceeding the expected 2-3%.
This case shows how MDR data drives real-world decisions. Without consistent reporting, the problem might have gone undetected until thousands were affected.
One non-obvious fact: MDR reports are not confidential. While personal identifiers are redacted, the device name, model, and event description are publicly searchable in the MAUDE database. This transparency supports independent research and public awareness.
I once reviewed MDR submissions for a startup developing a wearable ECG monitor. During testing, a prototype falsely flagged atrial fibrillation in 12% of healthy users. We filed an MDR report within 15 days, including raw data and algorithm logs. The FDA later referenced our submission in guidance on AI-based diagnostic tools.
For healthcare professionals, understanding MDR is essential. If you're involved in device use, you're part of the safety network. Even a single report can prevent harm to others.
For those managing device safety programs, regular training on MDR thresholds and submission workflows reduces compliance risks. The FDA provides free webinars and templates through its Center for Devices and Radiological Health (CDRH).
When evaluating device safety, consider both clinical outcomes and reporting patterns. A device with low failure rates but high MDR volume may signal poor user training or flawed design. Always cross-reference MDR data with other sources like peer-reviewed journals or post-market surveillance studies.